The Late Stage Chronic Kidney Disease Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Late Stage Chronic Kidney Disease Drugs Market:
According to The Business Research Company’s Late Stage Chronic Kidney Disease Drugs Global Market Report 2024, The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $6.38 billion in 2023 to $7.16 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to improvements in diagnostic capabilities, aging population, increased prevalence of diabetes and hypertension, growing awareness of kidney diseases, expansion of pharmaceutical research and development..
The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $10.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to rising healthcare expenditure, adoption of precision medicine approaches, increasing focus on regenerative medicine, growing emphasis on patient-centered care, global initiatives for kidney disease awareness.. Major trends in the forecast period include expansion of regenerative medicine therapies, rise in telemedicine services for ckd management, development of combination therapies, emphasis on early intervention strategies, growing interest in biomarker-based diagnostics.
The high prevalence of chronic kidney diseases is expected to propel the growth of the late-stage chronic kidney disease drug market going forward. Chronic kidney diseases refer to a diverse range of conditions that affect the structure and operation of the kidneys. Late-stage chronic kidney disease drugs for chronic kidney disease are used to control blood pressure in patients and decrease protein loss to halt the progression of kidney impairment, manage symptoms, and avoid consequences. For instance, in July 2022, according to Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, around 15%, or 37 million people in the US, were affected by kidney disease. The prevalence among individuals aged 45–64 is 12%, and people between 18 and 44 have the lowest majority of 6% in 2021. Therefore, the prevalence of chronic kidney disease is driving the growth of the late-stage chronic kidney disease drug market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp
The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Product innovation is a key trend gaining popularity in the late-stage chronic kidney disease drug market. Major companies operating in the late-stage chronic kidney disease drug market are developing new product drugs to sustain their position in the market. For instance, in February 2022, Bayer, a Germany-based pharmaceutical and biotechnology company, launched Kerendia (finerenone) in India. Patients with type two diabetes and chronic renal disease should use finer enone, a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist. It works by preventing the overactivation of the mineralocorticoid receptor (MR), which is thought to be a factor in developing chronic kidney disease (CKD) and cardiovascular harm.
The late stage chronic kidney disease drugs market report table of contents includes:
.
.
.
Top Major Players:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The medical terminology software global market report 2024 from The Business Research Company provides comprehensive…
The apples global market report 2024 from The Business Research Company provides comprehensive market statistics,…
The ip video surveillance and vsaas global market report 2024 from The Business Research Company…
The change and configuration management global market report 2024 from The Business Research Company provides…
The generative ai in gaming global market report 2024 from The Business Research Company provides…
The electric blankets global market report 2024 from The Business Research Company provides comprehensive market…